BioTechnique is a clinical-stage oncolytics company that is focused on discovering and developing novel therapies to treat patients with cancer. Using a next generation nanotechnology drug delivery platform, the company is developing therapies designed to reduce adverse effects associated with traditional chemotherapies and provide a targeted delivery to the tumor location. We are now raising capital to allow us to expand. We are welcoming accredited investors for our second private placement. Our private placement is being managed by Victor Cuilic of Uplift Partners at firstname.lastname@example.org. Please contact our CEO, Mr. John Clapham, for more details regarding this private placement at +1 (626) 786-7035, or jclapham@BioTechnique.com. All private placements shall comply with the US Securities Exchange Commission (SEC) regulations.
- 10 minutes of leisurely activity per week may lower death risk March 20, 2019New observational research in a large cohort has found a strong link between leisurely physical activity — even in low amounts — and a lower death risk.
- CBD for cancer: Everything you need to know March 19, 2019Cannabidiol, or CBD, is a compound in the cannabis plant. It may benefit people with cancer by reducing symptoms of the disease and its treatment. Learn more about the research here.
- How destroying a tumor promoter could lead to new cancer treatments March 19, 2019Mutated p53 tumor suppressor protein is a key driver of most cancers. Now, scientists have identified its mechanism of stability and how to disrupt it.
- What are the early symptoms of cancer in men? March 19, 2019Men have a higher risk of dying from cancer than women in the United States. However, recognizing the early signs can significantly improve a person’s outlook. Early symptoms of cancer in men can include changes in bowel habits, unexplained weight loss, testicular changes, and difficulties urinating. Learn more here.
- Coffee chemicals could curb prostate cancer March 18, 2019Coffee is a complex cocktail of compounds. A recent study identifies two particular molecules that might have cancer-fighting capabilities.